<DOC>
	<DOCNO>NCT00344786</DOCNO>
	<brief_summary>CLL dose escalate study ; daily dosing schedule ; PK/PD safety</brief_summary>
	<brief_title>Phase 1 , Dose-Escalation Study Oral CNF2024 ( BIIB021 ) CLL</brief_title>
	<detailed_description>Phase 1 , open-label , accelerated-titration study design evaluate effect increase dos CNF2024 safety , pharmacokinetics , pharmacodynamic marker , hematological response</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Patients CLL relapse follow intolerant purine analog base therapy Hemoglobin &gt; =9 gm/dL ( may posttransfusion ) Total bilirubin &lt; 2 X ULN , ALT AST &lt; 2 x ULN Creatinine &lt; =2 X ULN Normal plasma cortisol ACTH concentration ECOG Performance Status &lt; =2 Anticipated survival &gt; =3 month For men woman childproducing potential , use effective contraceptive method study one month treatment Ability understand requirement study , provide write informed consent authorization use disclosure protect health information , agree abide study restriction return required assessment Pregnant nursing woman Treatment chemotherapy , monoclonal antibody , radiotherapy within 28 day enter study Participation investigational drug study within 28 day CNF2024 administration Patients secondary malignancy require active treatment ( except hormonal therapy ) Active symptomatic bacterial , fungal , viral infection include active HIV viral ( A , B , C ) hepatitis Problems swallow malabsorption Diarrhea ( excess 23 stools/day normal frequency past month ) Gastrointestinal diseases include gastritis , ulcerative colitis , Crohn 's disease , hemorrhagic coloproctitis Major surgery stomach small intestine Adrenal dysfunction Patients life functionthreatening CLL complication ( e.g. , cord compression , hemolytic crisis , urinary tract obstruction ) Any illness condition opinion investigator may affect safety treatment evaluation study 's endpoint</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>CLL</keyword>
	<keyword>CNF2024</keyword>
	<keyword>Hsp90 inhibitor</keyword>
</DOC>